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The impact of a cancer Survivorship Care Plan
on gynecological cancer patient and health care
provider reported outcomes (ROGY Care):
study protocol for a pragmatic cluster
randomized controlled trial
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Brenda M Pijlman9, Harrie WH Feijen10, Helena JMM Mertens11, Willem E Nolting12, Johannes J van Beek13,
Jan A Roukema1,14 and Roy FPM Kruitwagen15
Abstract
Background: There is a need for improvement of information provision and post-treatment care for cancer
survivors. A Survivorship Care Plan (SCP) is recommended by the American Institute of Medicine and the Dutch
Health Council, which is a summary of patients’ course of treatment as a formal document, and includes
recommendations for subsequent cancer surveillance, management of late effects, and strategies for health
promotion. Until now, evidence on the effects of implementing the SCP in clinical practice is lacking. The rationale
and study design of a pragmatic cluster randomized trial, aiming to assess the impact of SCP care in routine
clinical practice, is presented.
Methods/Design: A web-based patient registration system ‘Registrationsystem Oncological GYnecology’ (ROGY) is
used by gynecologists in the South of the Netherlands since 2006. A personalized SCP can automatically be
generated out of ROGY. In this pragmatic cluster randomized controlled trial, 12 hospitals are randomized to either
‘usual care’ or ‘SCP care’. In patients with ‘usual care’, the gynecologist provides care as usual. In patients with ‘SCP
care’, information about the tumor stage and treatment is personally discussed with the patient and a document is
handed to the patient. Prospectively, all patients diagnosed with endometrial or ovarian cancer in the participating
hospitals will be approached for study participation. Patients will complete questionnaires after surgery, and before
additional treatment, and after 6, 12, 18 and 24 months. In addition, health care providers will be asked their
opinion about implementation of SCP care. Primary outcome is defined as patient satisfaction with information
provision and care. Secondary outcomes are illness perception, health-related quality of life, health care use,
prevalence, course and referral rate of survivors with psychosocial distress, and health care providers’ evaluation of
SCP care.
Discussion: The ROGY Care trial will help to gain insight into the impact of SCP care on patient reported
outcomes, and on the evaluation of cancer survivors and health care providers of the different elements of the
SCP. Therefore, results will contribute to efforts to improve quality of care for cancer survivors.
Trial registration: Trial Registration: http://www.ClinicalTrials.gov. Identifier: NCT01185626
Medical Research Ethics Committee Reference Number: NL33429.008.10 Grant Reference Number: UVT2010-4743
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Background
Due to earlier diagnoses and improved treatments, the
number of cancer survivors is rapidly increasing in the
Western world. In 2000, there were about 400,000 can-
cer survivors in The Netherlands, and this number is
expected to increase to 700,000 in 2015 [1]. Neverthe-
less, these cancer survivors remain at risk for adverse
long-term or late effects of cancer diagnosis and treat-
ment in many physical and psychosocial domains. Qual-
ity of life and patient reported outcomes are increasingly
acknowledged to be important indicators of treatment
efficacy [2], especially since many new therapies only
marginally improve survival rates. Furthermore, little is
known about the quality of life, psychosocial well-being,
and health care needs of the increasing cohort of long-
term cancer survivors [3]. There is a need for optimizing
the transition from cancer patient to cancer survivor by
improving the coordination of post-treatment care for
cancer survivors. In the report ‘Follow-up in oncology’
[4], the Dutch Health Council states that the main goal
of aftercare is to provide information and identify and
treat the long-term effects of cancer or its therapy.
Although psychosocial care is considered to be of major
importance, the optimum form during aftercare remains
uncertain. According to the Dutch Health Council it is
necessary to encourage and give priority to research in
this area.
A key factor in the support for cancer survivors is
information provision. The information given to cancer
survivors about their type of cancer, treatment, possible
long-term and late effects and referral services can influ-
ence their illness perception and quality of life. It can
result in better informed decision making, lower levels
of depression and anxiety [5], improved satisfaction with
care, sense of control, and quality of life [6]. However,
the number of studies that have investigated these asso-
ciations is limited [7]. Health care providers are often
still reluctant to give a full amount of information about
prognoses and negative side effects of cancer and its
treatment [8]. Although the number of studies that
include long-term cancer survivors and their informa-
tion needs are scarce, results from a few very recent stu-
dies suggest that most cancer survivors want more
information than is provided by specialists [5,9-11].
These studies underline the importance of a patient-tai-
lored approach to information provision. Providing
information that is congruent with a patient’s needs at
that particular time is an important determinant for
patient satisfaction and affects health-related quality of
life (HRQoL) and anxiety and depression levels of can-
cer survivors [12].
An approach to aftercare for cancer survivors recom-
mended by both the American Institute of Medicine
(IOM) and Health Council of the Netherlands is the
Survivorship Care Plan (SCP). An SCP provides cancer
survivors completing primary care with a summary of
their course of treatment as a formal document that
also includes recommendations for subsequent cancer
surveillance, management of late effects, and strategies
for health promotion. Essential in such an SCP is
detailed information provision about diagnosis and
treatment of cancer, possible long-term and late effects,
life-style recommendations, and available resources [13].
Based on its ‘face validity’, the IOM recommends that
SCPs become standard of care, as they are likely to
improve care [13]. The Dutch Health Council advises
the implementation of SCPs for each cancer survivor in
the Netherlands. The SCP is expected to be an empow-
ering and enabling device, by facilitating better under-
standing and self-care by the patient. However, evidence
concerning the positive and negative effects of the
implementation of the SCP in daily clinical practice is
lacking. As such, both the IOM and Health Council also
recommend studies for the evaluation of the impact of
SCPs on patient and health care provider reported out-
comes. Literature suggests a patient-tailored approach to
be optimal when providing prognosis or treatment sum-
maries [12]. Health communication strategies, such as
SCPs, may have excellent potential to meet the informa-
tion needs of the increasing group of cancer survivors,
and are likely to improve their quality of life [9]. Never-
theless, the psychological impact of these strategies on
patient reported outcomes such as perceived quality of
information provision, quality of care, quality of life and
health care use remains unknown. As such, prospective
evaluations of these strategies need to be conducted [9].
Therefore, it is necessary to assess the impact of SCP




The aim of the proposed study is to assess the impact of
SCP care on patient and health care provider reported
outcomes in routine clinical practice. Primary outcomes
include patients’ satisfaction with information provision,
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and satisfaction with care. Secondary outcomes include
patients’ health-related quality of life, illness perception,
health care use, prevalence, course and referral rate of
patients with psychosocial distress, and health care pro-
viders’ evaluation of the (implementation of the) SCP.
It is hypothesized that patients who receive SCP care
report better satisfaction with information provision,
better satisfaction with care, and more adequate illness
perception than those who receive usual care. It is
furthermore hypothesized that patients who receive SCP
care will report a higher health care use compared to
those receiving usual care [14]. In addition, it is
expected that patients who receive the SCP will report
less anxiety, less depression or psychosocial stress and
better HRQoL. However, there may be subgroups
(dependent on patient characteristics, such as age, edu-
cation, and personality) that will be influenced in a
negative way when receiving more information than
they can handle. Finally, it is hypothesized that patients
who receive SCP care are more adequately referred to
other health care services when they have high distress
levels compared to those who receive usual care.
Design
A pragmatic, cluster randomized controlled clinical trial
(RCT) will be conducted, in which 12 hospitals will be
randomized to either ‘usual care’ or ‘SCP care’. It will be
a longitudinal study, including patients immediately
after initial surgery and following them for 24 months.
The trial has been registered on http://www.Clinical-
Trials.gov (NCT01185626). The description of this
design follows the CONSORT recommendations for
reporting on trials (http://www.consort-statement.org)
with the extensions for pragmatic [15] and cluster [16]
randomized trials.
Study population
The RCT will be performed in a setting with gynecolo-
gical patients in 12 hospitals in the South of the Nether-
lands. These 12 hospitals, including teaching and non-
teaching hospitals, will be randomized to either ‘usual
care’ or ‘SCP care’. As defined by the US National Coali-
tion for Cancer Survivorship (NCCS), a cancer survivor
is: ‘A person diagnosed with cancer from the moment of
diagnosis through the balance of his or her life’ (http://
www.canceradvocacy.org). Following this definition, all
endometrial and ovarian cancer survivors from the 12
participating hospitals will be included immediately after
initial diagnosis and followed for 24 months. Survivors
with advanced cancer or those who develop a recur-
rence or metastasis will not be excluded, since they are
all considered to be cancer survivors according to the
NCCS definition.
Inclusion criteria
a) Age ≥ 18 years (no upper age limit)
b) Diagnosed with endometrial or ovarian cancer
Exclusion criteria
a) Patients with borderline ovarian cancer
b) Patients undergoing palliative care
c) Patients who are not able to complete a Dutch
questionnaire
Recruitment
Patients will be invited to participate in the study by
their own gynecologist, after initial diagnosis. The gyne-
cologists will send all their patients the first question-
naire, together with a letter and leaflet to inform them
about the study and an informed consent form. The let-
ter and accompanying leaflet about the study will be
rather generic, stating the study’s objective to investigate
the quality of life of cancer survivors. Patients can fill in
the informed consent form and complete the question-
naire by pencil and paper and send it back to the
researchers in a pre-stamped envelope. If they prefer
online completion, they can complete the questionnaire
via the PROFILES (Patient Reported Outcomes Follow-
ing Initial treatment and Long term Evaluation of Survi-
vorship) website http://www.profielstudie.nl[17] after
secured login, for which they are provided with a link
and password. To guarantee anonymity, returned ques-
tionnaires contain only a study number. If the question-
naire is not returned within 1 month, a reminder will be
sent, again by the treating gynecologist. After the initial
contact via the gynecologist and obtaining informed
consent, the follow-up questionnaires at 6, 12, 18 and
24 months after diagnosis will be sent directly to the
home address of the patient.
Randomization
Hospitals have been pre-randomized whereby patients
from a certain hospital will receive either usual care and
information provision or an SCP. With this so-called
pre-randomization, the conventional sequence of obtain-
ing informed consent followed by randomization is
reversed [18]. Pre-randomization is justified if valid eva-
luation of the effects of an intervention is impossible
using a conventional randomized design, for example if
knowledge of the intervention may lead to non-compli-
ance or drop-out in the control group, or when the
intervention is an educational program [18]. Pre-rando-
mization at hospital level eliminates the problem posed
by randomization at patient level in which health care
providers from a hospital have to provide both types of
care. By having to switch between usual care and SCP
care for each patient, the health care provider could
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(unconsciously) influence the usual care group with that
of the SCP approach by giving a patient randomized to
usual care more information than was intended for
usual care. Also, if usual care patients learn from other
patients that they are given an SCP, it is possible that
they will become dissatisfied with their usual care, even
if the (dis)advantages are not well studied. This would
bias the results of the study. To prevent imbalance
between the treatment groups, stratified randomization
was performed according to whether a hospital has a
Gynecologic Oncology Center, and the annual number
of endometrial and ovarian cancer patients, allowing for
an even distribution of the intervention through the dif-
ferent participating centers.
Randomization to either usual care or SCP care at
hospital level was performed with a table of random
numbers by a researcher not involved in the study and
blind to the identity of the hospitals. Because the health
care providers administering the intervention have to
know whether they have to provide either usual care or
SCP care, it was not possible for them to be blinded to
the group assignment. The participants on the other
hand are unaware of the group assignment, as they are
under the assumption that the hospital is providing
usual care.
Intervention versus usual care
Usual care: The health care provider (i.e., gynecologist
or oncology nurse) provides care as usual. Currently, the
12 involved hospitals provide follow-up following the
Dutch guidelines http://www.oncoline.nl, meaning that
they see their patients on given time points based on
the number of years after diagnosis. Most of the partici-
pating hospitals give their patients leaflets regarding the
diagnosis and treatment they receive. However none of
them provide personalized printed information. All
information is given during the initial treatment phase,
but none of the health care providers give additional
information during follow-up, except for ad-hoc refer-
rals if needed by the patient. Most of the health care
providers are not actively screening on psychosocial
needs. As the usual care and information provision in
these hospitals might change in time, the health care
providers and patients will be asked about the type of
information (e.g., brochures, DVDs, websites, persona-
lized information) and psychosocial care they provide
and receive, respectively.
SCP care: The health care provider (i.e., gynecologist
or oncology nurse) provides the patient with a paper
SCP after initial treatment, and discusses all the items in
the SCP with the patient. To improve communication,
the health care provider also sends a copy of the SCP to
the patient’s general practitioner. In follow-up consulta-
tions, the patient will receive an updated SCP if
applicable. The health care providers involved in the
SCP arm attended an instruction-evening to enhance
the complete use of the SCP, by providing them with
practical guidelines on how to discuss the SCP informa-
tion with patients. In addition, the health care providers
received a reminder, consisting of a summary of the
purpose of the SCP and the study, and practical guide-
lines of the use of the SCP, intended to remind the
health care providers to provide an SCP to their
patients. As this is a pragmatic trial aiming to assess the
impact of SCP care in daily clinical practice, the delivery
of the intervention is allowed to vary between health
care providers. The health care providers have the flex-
ibility to discuss the SCP according to the patients’
needs.
ROGY Survivorship Care Plan
For the development of the SCP used in this RCT, the
Dutch SCP template, which is very similar to the format
that was described by the IOM [13], was adjusted to the
local situation as was suggested by Ganz [19]. A sub-
group of gynecologists, oncology nurses, a radiotherapist,
a medical oncologist, as well as a general practitioner and
a few patients adjusted a standardized SCP to the local
situation.
The paper SCP is extracted from the online registra-
tion system ‘ROGY’ (Registrationsystem Oncological
GYnecology) and provides tailored information based on
personal patient and disease data (e.g., name patient,
date of birth, type of cancer, cancer stage, treatment
received, providers involved). Detailed information is
provided on the diagnosis, treatment, possible short-
term and long-term effects of the disease and the treat-
ment, and aftercare. In addition, the Distress Thermo-
meter [20] is provided as an aid for the communication
about psychosocial distress between patients and health
care providers.
The SCP contains information that is tailored to the
specific situation of the patient. For instance, a patient
who received adjuvant radiotherapy will get information
about potential long-term effects of radiotherapy and
what to do if certain complaints arise. Recurrences, toxi-
cities or other specialists involved in the patient’s care
will be registered in ROGY and automatically updated
in the personal SCP.
The ROGY system was set up to facilitate patient
registration and improve patient care by means of uni-
form regional multidisciplinary patient consultation. For
each patient, a detailed registration is made, including
information about FIGO (International Federation of
Gynecology and Obstetrics) stage, grade, treatment,
complications, comorbidity and follow-up. Thus, all
necessary information for an SCP [12] is already routi-
nely registered by all participating gynecologists, in a
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uniform way. By pressing a button in ROGY, which is
only visible for the health care providers randomized to
SCP care, it is possible to automatically generate a per-
sonalized SCP from the information available in the
ROGY system. All gynecologists randomized to either
usual care or SCP care use this registration system, so
there will be no registration bias. Therefore, the possible
quality of care improvement that comes with detailed
registration is equal in both arms, and only the impact
of providing SCPs will be evaluated.
Patient reported outcomes
Outcomes will be assessed with standardized and vali-
dated measures shown to have acceptable psychometric
properties.
Satisfaction with information provision will be mea-
sured using the EORTC-INFO26 [21] module. This
questionnaire aims to evaluate the (satisfaction with)
information received by cancer patients on different
areas of the disease, diagnosis, treatment and care, and
some qualitative aspects, for instance wishes for more
information. The questionnaire contains the following
scales: (a) Information about the disease; (b) Information
about medical tests; (c) Information about treatment; (d)
Information on other services, and single items: (a)
Written information; (b) Information on CDs or tape/
video; (c) Satisfaction with the amount of information;
(d) Desire for more information; (e) Desire for less
information; (f) Helpfulness of information. Further-
more, a more specific question will be added about
whether patients have received an SCP, to control for
physician compliance with the provision of SCP care.
Cancer specific HRQoL will be measured with the
EORTC QLQ-C30 [22]. Much of the content of the
questionnaire is appropriate for extended monitoring of
health status, including scales assessing physical, cogni-
tive and emotional functioning, fatigue and sleep pro-
blems, and overall health and quality of life. This core
instrument is supplemented by a condition-specific
questionnaire module. For endometrial cancer, the
EORTC-EN24 [23] module will be used. This module
assesses lymphoedema, urological symptoms, gastroin-
testinal symptoms, body image, sexual/vaginal symptoms,
back/pelvic pain, and chemotherapy side effects. For ovar-
ian cancer, the EORTC-OV28 module [24] will be used,
which measures abdominal/gastrointestinal symptoms,
peripheral neuropathy, other chemotherapy side-effects,
hormonal/menopausal symptoms, body image, attitude to
disease/treatment and sexual functioning.
Satisfaction with care will be measured with the
EORTC IN-PATSAT32 [25]. This questionnaire was
designed to assess cancer patients’ perception of
the quality of medical care, nursing care and care organi-
zation and services received in the hospital. The EORTC
IN-PATSAT32 contains 11 multi-item and 3 single-item
scales. These include the doctors’ technical skills, inter-
personal skills, information provision, and availability; the
nurses’ technical skills, interpersonal skills, information
provision, and availability; the other hospital staff’s inter-
personal skills and information provision scale; the
exchange of information single-item scale; the waiting
time; the hospital access; the comfort single-item scale;
and the general satisfaction single-item scale.
Illness perception will be measured using the Brief Ill-
ness Perception Questionnaire (B-IPQ) [26]. The scale
has 9 items, measuring (a) cognitive representations
(consequences, timeline, personal control, treatment
control, identity); (b) emotional representations (con-
cern, emotion); (c) illness comprehensibility; and (d) an
open-ended response item on the 3 most important cau-
sal factors of illness.
Comorbidity at the time of questionnaire completion
will be assessed by the adapted Self-administered
Comorbidity Questionnaire (SCQ) [27]. Patients will be
asked to identify comorbid conditions developed in the
past 12 months. The adapted SCQ lists 14 medical con-
ditions (with the option to list up to 3 additional condi-
tions), and assesses if the patient is treated for the
comorbid condition and the perceived impact on the
patients’ functioning.
Anxiety and depression will be assessed using the Hos-
pital Anxiety and Depression Scale (HADS) [28]. The
HADS has 14-items, with 7 items each for anxiety and
depression. Each item is scored from 0 to 3, where a
score of 3 represents a state corresponding to the worst
anxiety or depression. The sum of these items produces
two subscales ranging from 0 to 21. A score of 8 will be
used as a cut-off value for both depression and anxiety
[28].
Physical and mental fatigue will be measured using
the Fatigue Assessment Scale (FAS) [29], which consists
of 10-items with 5 items each reflecting physical and
mental fatigue. The items are scored on a 5-point
response scale ranging from 1 (never) to 5 (always).
Personality will be measured with the DS14 [30] which
has 14 items ranged on a 5-point response scale ranging
from 0 (false) to 4 (true). Seven of these items refer to
‘Negative Affectivity’ or the tendency to experience
negative emotions in general (e.g., ‘I am often down in
the dumps or I often find myself worrying about some-
thing’). The remaining 7 items refer to the patient’s level
of ‘Social Inhibition’, or the tendency to inhibit the
expression of emotion/behavior in social relationships
(e.g., ‘I am a closed kind of person or I often feel inhib-
ited in social interactions’). According to previously pub-
lished cut-off scores, patients were diagnosed as Type D
if they scored ≥10 on both the Negative Affectivity and
Social Inhibition scales.
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Health care utilization will be assessed by patients’
frequency and reason (cancer-related or not) for contact
with their general practitioner or medical specialist in
the past 12 months. Patients will be asked whether they
have been referred to other health care services.
Additional measures include demographic and socioeco-
nomic variables such as age, education, marital status, and
employment status, and clinical variables such as cancer
stage at diagnosis, time after diagnosis, and initial treat-
ment. All measures will be collected at the beginning of
the trial, and at 6, 12, 18 and 24 months after diagnosis.
Health care providers’ evaluation
Gynecologists and oncology nurses in both arms will be
asked their opinion about the implementation of SCP
care or usual care. At the beginning of the trial and
after 12 months, gynecologists and oncology nurses will
be asked to fill in a short questionnaire containing ques-
tions about the type of information they provide, how
satisfied they are with the information they provide,
how much time they spend on their consultations on
average, to what extent they expect the SCP care to
have a positive effect on patients, and how motivated
they are to use the SCP. In addition, at the end of
patient inclusion after 12 months, all gynecologists and
oncology nurses in the SCP arm are invited to partici-
pate in qualitative interviews on their opinion about (the
implementation of) the SCP care.
General practitioners of patients in both arms will be
asked to fill in a short questionnaire, containing ques-
tions about whether they received the SCP and whether
they believe it has improved the communication
between themselves and the gynecologist, and between
themselves and their patient.
Sample size
The initial patient inclusion will be completed in
approximately one year. Each year, approximately 250
endometrial and 200 ovarian cancer survivors are diag-
nosed in the participating hospitals. Based on previous
studies [31-34] 337 patients (75%) are minimally
expected to participate in one year. Allowing for 10%
attrition, this equates about 300 patients. Assuming an
average practice size, the power will be 0.98 to detect a
minimum effect size of 0.5, which is considered clini-
cally significant [35]. In addition, separate analyses for
endometrial and ovarian cancer survivors can be con-
ducted: 150 patients are sufficient to detect a half stan-
dard deviation difference with a power of 0.83.
Statistical analysis
Analyses will be performed adhering to the intention-to-
treat principle. Descriptive statistics will be used to sum-
marize characteristics of both hospitals and patients.
Characteristics of patients (i.e., age, type of cancer,
stage, treatment, socio-economic status, marital status,
educational level, employment status) and hospitals (i.e.,
number of endometrial and ovarian cancer patients,
whether a hospital is a training hospital) will be com-
pared at baseline between the intervention and usual
care group, by regression analyses.
Linear regression models will be used to analyze con-
tinuous outcome variables, and logistic models for bin-
ary outcome variables. All analyses will be adjusted for
hospital, baseline values of the outcome measure, and
baseline variables which differ to a clinically significant
extent between groups. Differential effects of SCP care
by age, type of cancer and baseline levels of the out-
comes of interest will be assessed for the outcome mea-
sures by adding terms for the interaction between age,
educational level, personality, type of cancer and base-
line levels and care arm to the regression models.
A multilevel modeling approach [36] will be applied to
evaluate differences between the intervention group and
the control group. This approach will be used to take
into account the clustering at the hospital level [37]. All
statistical tests will be two-sided and considered signifi-
cant if p<0.05. Repeated measures analysis using gener-
alized estimating equations will be conducted to
account for the intra-patient dependency of the repeated
measures [38]. Differences in effect of the SCP care and
usual care at the different time points will also be inves-
tigated [38].
Missing outcome data will be assumed to be ‘missing
at random’ (MAR), conditional on key predictors of
‘missingness’ (in particular baseline values of the out-
come variables of interest, and care arm). Clinically
meaningful differences will be determined with Nor-
man’s ‘rule of thumb’, whereby a difference of ≈0.5 SD
indicates a threshold of discriminant change in health
status scores of a chronic illness [35].
Routinely collected data from the population-based
Eindhoven Cancer Registry (ECR) and ROGY on patient
and tumor characteristics will allow for the comparison
of respondents, non-respondents and patients with
unverifiable addresses, using t-tests for continuous vari-
ables and Chi-square analyses for categorical variables.
Ethical considerations
The study protocol has been approved by the medical
research ethics committees of the participating centers
(Medical Research Ethics Committee reference number:
NL33429.008.10). The study will be conducted accord-
ing to the Declaration of Helsinki, as amended in 2008
by the World Medical Association, and all patients will
be informed about the purpose, rights, and possible ben-
efits/risks of the study. Study participation of patients is
voluntary and can be cancelled at any time without
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provision of reasons and without any consequences.
Patients can call a psychologist, an epidemiologist, or an
independent general practitioner for more information
about the study.
Data security/disclosure of original documents
Confidentiality and anonymity of participants will be guar-
anteed with the assignation of a study number to each par-
ticipant. As such, returned questionnaires have no names
attached and will be linked to data from the ECR by study
number. Therefore, it will not be possible for the research-
ers to track participants’ names with the study numbers.
The results of the patient questionnaires are not accessible
to the gynecologists or other health care providers. Ques-
tionnaires are directly mailed to the study center by the
patients. Returned questionnaires will be stored in a
secured location for five years. Only direct members of the
internal study team can access the respective files.
Discussion
The number cancer survivors that are confronted with
adverse long-term or late effects is rapidly increasing.
These cancer survivors remain at risk for adverse long-
term or late effects of cancer diagnosis and treatment,
and often do not know how to interpret their physical
or psychosocial problems, or where to go for support.
Providing patients with an SCP may be an empowering
and enabling instrument, by facilitating better under-
standing and self-care by the patient. However, evidence
concerning the effects of the implementation of the SCP
in daily clinical practice is lacking. It is therefore neces-
sary to assess the impact of SCP care in routine clinical
practice before its large-scale implementation.
If this study shows that SCP care is feasible and effec-
tive, this scientific evidence can be used to convince
cancer survivors’ health care providers and health insur-
ance companies about the benefits of implementing SCP
care. The results will help to gain insight into the
impact of SCP care on patient reported outcomes, and
on the evaluation of cancer survivors and health care
providers of the different elements of the SCP. There-
fore, results will contribute to efforts to improve quality
of care for cancer survivors.
Trial status
The inclusion of patients started April 2011. The initial
patient inclusion will be completed in approximately
one year. Patients will be followed for two years.
Links
ClinicalTrials.gov http://www.ClinicalTrials.gov
National Coalition for Cancer Survivorship http://
www.canceradvocacy.org
CONSORT recommendations for reporting on trials
http://www.consort-statement.org
PROFILES http://www.profielstudie.nl
Oncoline - Cancer Clinical Practice Guidelines http://
www.oncoline.nl
List of abbreviations
CCCS: Comprehensive Cancer Center South; ECR: Eindhoven Cancer Registry;
HRQoL: Health-Related Quality of Life; IOM: American Institute of Medicine;
MAR: Missing At Random; NCCS: National Coalition for Cancer Survivorship;
OOG-CCCS: Organization Oncologic Gynecology of the Comprehensive
Cancer Center South; RCT: Randomized Controlled Trial; ROGY:
Registrationsystem Oncological GYnecology; SCP: Survivorship Care Plan.
Acknowledgements
This trial is supported with grant no. UVT 2010-4743 from the Dutch Cancer
Society, The Netherlands. Dr. Lonneke van de Poll-Franse is supported by a
Cancer Research Award from the Dutch Cancer Society (#UVT-2009-4349).
We would like to thank the following hospitals and institutions for their
cooperation: Amphia Hospital, Breda and Oosterhout; Catharina Hospital,
Eindhoven; Elkerliek Hospital, Helmond; Jeroen Bosch Hospital, ‘s-
Hertogenbosch; Institute Verbeeten, Tilburg; Maastricht University Medical
Center, Maastricht; Maxima Medical Center, Eindhoven and Veldhoven; Orbis
Medical Center, Sittard; St. Anna Hospital, Geldrop and Eindhoven; St.
Elisabeth Hospital, Tilburg; St. Jans Hospital, Weert; TweeSteden Hospital,
Tilburg and Waalwijk; VieCuri Hospital, Venlo and Venray.
Author details
1CoRPS - Center of Research on Psychology in Somatic diseases, Department
of Medical Psychology, Tilburg University, Tilburg, The Netherlands.
2Eindhoven Cancer Registry, Comprehensive Cancer Center South (CCCS),
Eindhoven, The Netherlands. 3Department of Gynecology, St. Elisabeth
Hospital, Tilburg, The Netherlands. 4Department of Gynecology, TweeSteden
Hospital, Tilburg and Waalwijk, The Netherlands. 5Department of Gynecology,
Maxima Medical Center, Veldhoven and Eindhoven, The Netherlands.
6Department of Gynecology, Catharina Hospital, Eindhoven, The Netherlands.
7Department of Gynecology, St. Anna Hospital, Geldrop and Eindhoven, The
Netherlands. 8Department of Gynecology, Elkerliek Hospital, Helmond, The
Netherlands. 9Department of Gynecology, Jeroen Bosch Hospital, ‘s-
Hertogenbosch, The Netherlands. 10Department of Gynecology, Amphia
Hospital, Breda and Oosterhout, The Netherlands. 11Department of
Gynecology, Orbis Medical Center, Sittard, The Netherlands. 12Department of
Gynecology, St. Jans Hospital, Weert, The Netherlands. 13Department of
Gynecology, VieCuri Hospital, Venlo and Venray, The Netherlands.
14Department of Surgery, St. Elisabeth Hospital, Tilburg, The Netherlands.
15Department of Gynecology and GROW - School for Oncology and
Developmental Biology, Maastricht University Medical Center, Maastricht, The
Netherlands.
Authors’ contributions
In collaboration with the OOG-CCCS (Organization Oncologic Gynecology of
the Comprehensive Cancer Center South), LP, CV, DB, JP, OH, AR, and RK
contributed to the design of the study and provided the basis for the
intervention. All authors contributed to the development of the trial
protocol and data collection. LP and KN drafted the manuscript. All authors
provided input into revisions of the manuscript and have approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 12 September 2011 Accepted: 5 December 2011
Published: 5 December 2011
References
1. Signaleringscommissie kanker van KWF Kankerbestrijding: Kanker in
Nederland. Trends, prognoses en implicaties voor zorgvraag Amsterdam; 2004.
van de Poll-Franse et al. Trials 2011, 12:256
http://www.trialsjournal.com/content/12/1/256
Page 7 of 8
2. Ayanian JZ, Jacobsen PB: Enhancing research on cancer survivors. J Clin
Oncol 2006, 24:5149-5153.
3. Gotay CC, Muraoka MY: Quality of life in long-term survivors of adult-
onset cancers. J Natl Cancer Inst 1998, 90:656-667.
4. Health Council of the Netherlands: Follow-up in oncology. Identify objectives,
substantiate actions The Hague; 2007.
5. Mesters I, van den Borne B, De Boer M, Pruyn J: Measuring information
needs among cancer patients. Patient Educ Couns 2001, 43:253-262.
6. Davies NJ, Kinman G, Thomas RJ, Bailey T: Information satisfaction in
breast and prostate cancer patients: implications for quality of life.
Psychooncology 2008, 17:1048-1052.
7. Hesse BW, Arora NK, Burke Beckjord E, Finney Rutten LJ: Information
support for cancer survivors. Cancer 2008, 112:2529-2540.
8. Meredith C, Symonds P, Webster L, Lamont D, Pyper E, Gillis CR,
Fallowfield L: Information needs of cancer patients in west Scotland:
cross sectional survey of patients’ views. BMJ 1996, 313:724-726.
9. Beckjord EB, Arora NK, McLaughlin W, Oakley-Girvan I, Hamilton AS,
Hesse BW: Health-related information needs in a large and diverse
sample of adult cancer survivors: implications for cancer care. J Cancer
Surviv 2008, 2:179-189.
10. Jenkins V, Fallowfield L, Saul J: Information needs of patients with cancer:
results from a large study in UK cancer centres. Br J Cancer 2001,
84:48-51.
11. Lagarde SM, Franssen SJ, van Werven JR, Smets EM, Tran TC, Tilanus HW,
Plukker JT, de Haes JC, van Lanschot JJ: Patient preferences for the
disclosure of prognosis after esophagectomy for cancer with curative
intent. Ann Surg Oncol 2008, 15:3289-3298.
12. Husson O, Mols F, van de Poll-Franse LV: The relation between
information provision and health-related quality of life, anxiety and
depression among cancer survivors: a systematic review. Annals of
Oncology .
13. Hewitt M, Greenfield S, Stovall E: From cancer patient to cancer survivor: Lost
in transition Washington, DC; 2006.
14. Tan ASL, Bourgoin A, Gray SW, Armstrong K, Hornik RC: How does patient-
clinician information engagement influence self-reported cancer-related
problems? Cancer .
15. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B,
Oxman AD, Moher D, for the CONSORT and Pragmatic Trials in Healthcare
(Practihc) groups: Improving the reporting of pragmatic trials: an
extension of the CONSORT statement. BMJ 2008, 337:a2390.
16. Campbell MK, Elbourne DR, Altman DG, for the CONSORT group: CONSORT
statement: extension to cluster randomized trials. BMJ 2004, 328:702-708.
17. van de Poll-Franse LV, Horevoorts N, van Eenbergen M, Denollet J,
Roukema JA, Aaronson NK, Coebergh JW, de Vries J, Essink-Bot M-L, Mols F:
The Patient Reported Outcomes Following Initial treatment and Long
term Evaluation of Survivorship registry: Scope, rationale and design of
an infrastructure for the study of physical and psychosocial outcomes in
cancer survivorship cohorts. Eur J Cancer 2011.
18. Schellings R, Kessels AG, Sturmans F: Pre-randomisation in study designs:
getting past the taboo. Ned Tijdschr Geneeskd 2008, 152:2053-2056.
19. Ganz PA, Hahn EE: Implementing a survivorship care plan for patients
with breast cancer. J Clin Oncol 2008, 26:759-767.
20. Tuinman MA, Gazendam-Donofrio SM, Hoekstra-Weebers JEHM: Screening
and referral for psychosocial distress in oncologic practice: Use of the
Distress Thermometer. Cancer 2008, 113:870-878.
21. Arraras JI, Kuljanic-Vlasic K, Bjordal K, Yun YH, Efficace F, Holzner B, Mills J,
Greimel E, Krauss O, Velikova G: EORTC QLQ-INFO26: a questionnaire to
assess information given to cancer patients a preliminary analysis in
eight countries. Psychooncology 2007, 16:249-254.
22. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ,
Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Rofe PB,
Schraub S, Sneeuw K, Sullivan M, Takeda F: The European Organization for
Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument
for use in international clinical trials in oncology. J Natl Cancer Inst 1993,
85:365-376.
23. Greimel E, Nordin A, Lanceley A, Creutzberg CL, van de Poll-Franse LV,
Radisic VB, Galalae R, Schmalz C, Barlow E, Jensen PT, Waldenström AC,
Bergmark K, Chie WC, Kuljanic K, Costantini A, Singer S, Koensgen D,
Menon U, Daghofer F: Psychometric validation of the European
Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). Eur J
Cancer 2011, 47:183-190.
24. Greimel E, Bottomley A, Cull A, Waldenstrom AC, Arraras J, Chauvenet L,
Holzner B, Kuljanic K, Lebrec J, D’haese S: EORTC Quality of Life Group and
the Quality of Life Unit. An international field study of the reliability and
validity of a disease-specific questionnaire module (the QLQ-OV28) in
assessing the quality of life of patients with ovarian cancer. Eur J Cancer
2003, 39:1402-1408.
25. Bredart A, Bottomley A, Blazeby JM, Conroy T, Coens C, D’Haese S, Chie WC,
Hammerlid E, Arraras JI, Efficace F, Rodary C, Schraub S, Costantini M,
Costantini A, Joly F, Sezer O, Razavi D, Mehlitz M, Bielska-Lasota M,
Aaronson NK: An international prospective study of the EORTC cancer in-
patient satisfaction with care measure (EORTC IN-PATSAT32). Eur J
Cancer 2005, 41:2120-2131.
26. Broadbent E, Petrie KJ, Main J, Weinman J: The brief illness perception
questionnaire. J Psychosom Res 2006, 60:631-637.
27. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN: The Self-Administered
Comorbidity Questionnaire: a new method to assess comorbidity for
clinical and health services research. Arthritis Rheum 2003, 49:156-163.
28. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta
Psychiatr Scand 1983, 67:361-370.
29. Michielsen HJ, de Vries J, van Heck GL: Psychometric qualities of a brief
self-rated fatigue measure: The Fatigue Assessment Scale. J Psychosom
Res 2003, 54:345-352.
30. Denollet J: DS14: standard assessment of negative affectivity, social
inhibition, and Type D personality. Psychosom Med 2005, 67:89-97.
31. van de Poll-Franse LV, Mols F, Essink-Bot ML, Haartsen JE, Vingerhoets AJ,
Lybeert ML, van den Berg HA, Coebergh JW: Impact of external beam
adjuvant radiotherapy on health-related quality of life for long-term
survivors of endometrial adenocarcinoma: a population-based study. Int
J Radiation Oncology Biol Phys 2007, 69:125-132.
32. Korfage IJ, Essink-Bot M-L, Mols F, van de Poll-Franse LV, Kruitwagen RFPM,
van Ballegooijen M: Health- related quality of life in cervical cancer
survivors: a population- based study. Int J Radiation Oncology Biol Phys
2009, 7(3):1501-1509.
33. Thong MSY, Mols F, Lemmens VEPP, Rutten HJT, Roukema JA, Martijn H,
van de Poll-Franse LV: Impact of preoperative radiotherapy on general
and disease-specific health status of rectal cancer survivors: a
population based study. Int J Radiation Oncology Biol Phys 2011.
34. Husson O, Holterhues C, Mols F, Nijsten T, van de Poll-Franse LV:
Melanoma survivors are dissatisfied with perceived information about
their diagnosis, treatment and follow-up care. British Journal of
Dermatology 2010, 163:879-881.
35. Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-
related quality of life: the remarkable universality of half a standard
deviation. Med Care 2003, 41:582-592.
36. Hox J: Multilevel Analysis: Techniques and Applications New York: Routledge;
2010.
37. Twisk JWR: Applied Multilevel Analysis. A Practical Guide Cambridge:
Cambridge University Press; 2006.
38. Twisk JWR: Applied longitudinal data analysis for epidemiology. A practical
guide Cambridge: Cambridge University Press; 2003.
doi:10.1186/1745-6215-12-256
Cite this article as: van de Poll-Franse et al.: The impact of a cancer
Survivorship Care Plan on gynecological cancer patient and health care
provider reported outcomes (ROGY Care): study protocol for a
pragmatic cluster randomized controlled trial. Trials 2011 12:256.
van de Poll-Franse et al. Trials 2011, 12:256
http://www.trialsjournal.com/content/12/1/256
Page 8 of 8
